Gongora et al. reported that SGLT2 inhibitor use was associated with fewer cardiac events, primarily driven by a reduction in heart failure admissions and new diagnoses of cardiomyopathy among patients with diabetes treated with anthracyclines [21]. Here, SLC5A2 is linked to cardiomyopathy.